日本語English简体中文 繁體中文

4893 Noile-Immune Biotech Inc.ノイルイミューン・バイオテックTSE Growth / Pharmaceuticals

0 posts

Noile-Immune Biotech Inc. (4893) at a glance

Code
4893
Company
Noile-Immune Biotech Inc.
Local name
ノイルイミューン・バイオテック
Market
TSE Growth
Sector
Pharmaceuticals
Share price
¥75.0 -3.00 (-3.85%) Nov 20 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

Noile-Immune Biotech Inc. (4893) Stock Price HistoryNear an all-time low

Noile-Immune Biotech Inc. closed at ¥75.0 on Nov 20, 2026, −16.7% over 1 month, −52.2% over 1 year.

2026-10-21 行使価額修正条項付新株予約権の大量行使に関するお知らせ2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(非連結)¥91.0¥75.0Oct 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
1-Month High¥91.0Oct 21
1-Month Low¥75.0Nov 20
1-Week Change−13.8%vs Nov 13
1-Month Change−16.7%vs Oct 20

If you had invested ¥100,000 1 month ago, it would be worth ¥83,333 today (−16.7%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −11.9%, while this stock moved −16.7%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥75.0−3−3.85%
Nov 19 (Thu)¥78.0+1+1.30%
Nov 18 (Wed)¥77.0−4−4.94%
Nov 17 (Tue)¥81.0+0+0.00%
Nov 16 (Mon)¥81.0−6−6.90%
Nov 13 (Fri)¥87.0+1+1.16%
Nov 12 (Thu)¥86.0+0+0.00%
Nov 10 (Tue)¥86.0+1+1.18%
Nov 9 (Mon)¥85.0+6+7.59%
Nov 6 (Fri)¥79.0−5−5.95%
2026-09-18 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権(行使価… / 新株予約権発行による資金調達に関する補足説明資料2026-10-05 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権 (行使価…2026-10-21 行使価額修正条項付新株予約権の大量行使に関するお知らせ2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(非連結)¥156¥75.0Aug 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥156Aug 31
3-Month Low¥75.0Nov 20
1-Month Change−16.7%vs Oct 20
3-Month Change−46.4%vs Aug 20

If you had invested ¥100,000 3 months ago, it would be worth ¥53,571 today (−46.4%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −14.8%, while this stock moved −46.4%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥75.0−3−3.85%
Nov 19 (Thu)¥78.0+1+1.30%
Nov 18 (Wed)¥77.0−4−4.94%
Nov 17 (Tue)¥81.0+0+0.00%
Nov 16 (Mon)¥81.0−6−6.90%
Nov 13 (Fri)¥87.0+1+1.16%
Nov 12 (Thu)¥86.0+0+0.00%
Nov 10 (Tue)¥86.0+1+1.18%
Nov 9 (Mon)¥85.0+6+7.59%
Nov 6 (Fri)¥79.0−5−5.95%
2026-09-18 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権(行使価… / 新株予約権発行による資金調達に関する補足説明資料2026-10-05 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権 (行使価…2026-10-21 行使価額修正条項付新株予約権の大量行使に関するお知らせ2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(非連結)¥156¥75.0May 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥156Aug 31
6-Month Low¥75.0Nov 20
3-Month Change−46.4%vs Aug 20
6-Month Change−41.4%vs May 20

If you had invested ¥100,000 6 months ago, it would be worth ¥58,594 today (−41.4%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −5.6%, while this stock moved −41.4%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥75.0−11.8%
Oct 2026¥85.0−27.4%
Sep 2026¥117−25.0%
Aug 2026¥156+12.2%
Jul 2026¥139+16.8%
Jun 2026¥119−11.9%
May 2026¥135−11.2%
2026-09-18 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権(行使価… / 新株予約権発行による資金調達に関する補足説明資料2026-10-05 第三者割当によるノイルイミューン・バイオテック株式会社第14回新株予約権 (行使価…2026-10-21 行使価額修正条項付新株予約権の大量行使に関するお知らせ2026-11-13 2026年12月期 第3四半期決算短信〔日本基準〕(非連結)¥205¥75.0Nov 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥205Mar 16
52-Week Low¥75.0Nov 20
Year to Date−43.6%vs Dec 30
From 52-Week High−63.4%Mar 16

If you had invested ¥100,000 1 year ago, it would be worth ¥47,771 today (−52.2%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +13.3%, while this stock moved −52.2%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥75.0−11.8%
Oct 2026¥85.0−27.4%
Sep 2026¥117−25.0%
Aug 2026¥156+12.2%
Jul 2026¥139+16.8%
Jun 2026¥119−11.9%
May 2026¥135−11.2%
Apr 2026¥152+5.6%
Mar 2026¥144−12.7%
Feb 2026¥165+11.5%
Jan 2026¥148+11.3%
Dec 2025¥133−17.9%
Nov 2025¥162―
¥397¥75.0Nov 20, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥397Nov 20, 2023
3-Year Low¥75.0Nov 20, 2026
Annualized Return−42.6%
Max Drawdown−81.1%

If you had invested ¥100,000 3 years ago, it would be worth ¥18,892 today (−81.1%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +67.8%, while this stock moved −81.1%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥75.0−43.6%
2025¥133―
¥630¥75.0Jun 26, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
5-Year High¥630Jul 3, 2023
5-Year Low¥75.0Nov 20, 2026
Annualized Return−45.7%
Max Drawdown−88.1%

If you had invested ¥100,000 5 years ago, it would be worth ¥12,500 today (−87.5%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +70.0%, while this stock moved −87.5%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥75.0−43.6%
2025¥133―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jun 2023). Please check the latest prices before trading.

Noile-Immune Biotech Inc. (4893) financial indicators

PBR
0.96
Dividend yield
0.00%

See all financial indicators for Noile-Immune Biotech Inc. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of Noile-Immune Biotech Inc. (4893)

Business overview

Guided by the principle of "contributing to a society that can overcome cancer," the company's main business is developing CAR-T cell therapies for solid tumors using its own technology. It applies PRIME technology, exclusively licensed from Yamaguchi University and its technology licensing organization Yamaguchi TLO, which is expected to deliver strong therapeutic effects by activating not only the administered CAR-T cells but also the immune cells in the patient's body. Its hybrid business model combines in-house drug discovery with joint pipelines in which it licenses PRIME technology to other companies. It operates a single cancer immunotherapy drug discovery segment.

Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR0.96xBelow the sector median of 1.86x (No. 19 from the lowest)
Market cap¥3.3 bnNo. 68 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥2053/16
52-week low¥7511/20
Current position0.0%Where the low is 0% and the high is 100% (close on 11/20: ¥75)
Year to date-43.6%No. 63 of 77 in the sector (best first)
1 year-52.2%

Based on closing prices (adjusted for stock splits, excluding dividends).

Kabutaro's ranking history

Top 50 losers3 timesLatest: 10/7 (No. 22)

Gainers and losers have been recorded since 9/2026.

Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Filings from the past 12 months (6).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the Noile-Immune Biotech Inc. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English